Leveraging deep domain expertise​

About Us

Hinge Bio, Inc. is a privately-held biotechnology company leveraging its powerful GEM-⁠DIMER™ platform to develop therapeutics that address the problems of inadequate efficacy and resistance in infectious disease and oncology.

The GEM-DIMER™ platform creates multivalent, multispecific antibody-based therapeutics that project freely into multidimensional space and cooperatively bind their disease target(s), enabling entirely new functionality for superior safety and efficacy.

Management Team

Carin Rollins

Carin Mueller Rollins, MBA

Co-Founder, Director & Chief Executive Officer

Ms. Rollins has more than 25 years of experience in the biotechnology industry, particularly in the areas of venture capital, management consulting and equity research. She was a co-founder of early-stage life science venture capital firm, 5AM Ventures, where she incubated and was a founding member of the Board of Directors of Marcadia (purchased by Roche) and KaloBios (IPO). She was previously an Investment Manager at Bay City Capital, an Associate in the pharmaceuticals practice of Booz Allen & Hamilton, and an Equity Research Associate at the investment bank Robertson Stephens & Co. Ms. Rollins holds a B.A. in Biology from Colgate University, where she served as a Trustee, and an MBA from the Stanford Graduate School of Business.

Daniel Capon

Daniel Capon, Ph.D.

Co-Founder, Director & Chief Scientific Officer

Dr. Capon is a molecular biologist with extensive experience in biotech invention and innovation. He holds forty-seven United States Patents covering recombinant Factor VIII for the treatment of hemophilia as well as several widely adopted foundational technologies including Fc fusion proteins, chimeric antigen receptors for T cell therapy, and genetically engineered mice using embryonic stem cells for the creation of fully human antibodies. His inventions have been broadly licensed and have led to the discovery and development of over twenty FDA-approved, marketed therapeutics including Enbrel for rheumatoid arthritis, Kymriah for B cell cancer, Vectibix for breast cancer, and Prolia/Xgeva for osteoporosis. Dr. Capon joined Genentech in 1981, serving in various positions including Staff Scientist and founding member of its Product Development Committee. He joined Cell Genesys in 1990, serving as Senior VP Research and Chief Technical Officer, and as a founder, director, and officer of Xenotech/Abgenix, a joint venture between Cell Genesys and Japan Tobacco, later acquired by Amgen for $2.2 billion. In 1995, Dr. Capon founded ViroLogic/Monogram Biosciences, today an operating subsidiary of LabCorp, serving as its Chairman and Chief Executive Officer to commercialize his invention of an HIV drug resistance diagnostic test used to guide HIV antiviral therapy. Dr. Capon has authored more than sixty peer-reviewed scientific publications. He received a B.S. in Biology and Ph.D. in Biochemistry from the Massachusetts Institute of Technology. 

Miriam Siekevitz

Miriam Siekevitz, Ph.D., J.D.

Co-Founder, General Counsel & Chief Administrative Officer

Ms. Siekevitz has more than 35 years of experience in science and the biotech industry with legal expertise in corporate, licensing, clinical and commercial matters. Ms. Siekevitz served as Corporate Counsel at PDL BioPharma, Inc., and its successor corporation, Facet Biotech Corporation. Previously, she was an Associate at Heller Ehrman White & McAuliffe LLP and a patent agent, technical consultant and visiting scientist at Cell Genesys, Inc. Prior to that, Ms. Siekevitz was an Assistant Professor in the Department of Microbiology at Mount Sinai School of Medicine in New York. She has 20 scientific publications and is a co-inventor on 4 U.S. patents. Ms. Siekevitz received her B.A. in Biology from the University of Chicago, her Ph.D. in Cell Biology from the Massachusetts Institute of Technology and her J.D. from the Stanford University Law School. She is admitted to practice before the U.S. Patent and Trademark Office and in the State of California. 

Richard Shames

Richard Shames, M.D.

Acting Chief Medical Officer

Dr. Shames has over 20 years of experience in the biotechnology/pharmaceutical industry, leading drug development programs across multiple immune/inflammatory indications. Previously he held leadership positions at Protagonist Therapeutics, Aldea Pharmaceuticals, Merck and Facet Biotech/PDL Biopharma. He has directed clinical development programs for FDA-approved products in chronic psoriasis, multiple sclerosis, and other autoimmune/inflammatory diseases. Dr. Shames previously held full-time faculty positions in Pediatric Allergy and Clinical Immunology at Stanford University Medical Center and the University of California, San Francisco School of Medicine. He completed post-doctoral training in Allergy and Clinical Immunology at U.C.S.F. and internship/residency in Pediatrics at Montefiore Hospital-Albert Einstein School of Medicine. Dr. Shames received his M.D. from the University of California, Davis School of Medicine, and B.S. in Biological Sciences from Stanford University. 

Catherine Lucas

Catherine Lucas, Ph.D.

Vice President, Development

Dr. Lucas has more than 30 years of experience in science and in the biotechnology industry, leading research and development teams in the early development of novel biomolecules from research through IND approval and first-in-human testing. She has worked in a number of healthcare industries in diagnostics, biotechnology and drug delivery, and has led multiple national and international teams, in small start-up companies and large pharmaceutical companies. Dr. Lucas was Vice President of Technical Development at IGM Biosciences for 4 years and worked at ALZA and Johnson and Johnson as Vice President of Technical Development for 10 years, developing long-term implants for the delivery of biomolecules as well as non-invasive technologies for the delivery of biomolecules to the central nervous system. Previously, Dr. Lucas worked at Cell Genesys on chimeric antigen receptors and on fully human antibodies derived from the XenoMouse. She worked at Genentech Inc. from 1985 to 1993, notably as part of project teams responsible for developing Fc fusion proteins, and a candidate HIV vaccine project. Dr. Lucas holds a B.A. in Biochemistry and a Ph.D. in Neurochemistry from the University of Sciences in Paris, France. She completed her post-doctoral studies in neurochemistry at Stanford University. 

Robert Hershberg

Robert Hershberg, Ph.D.

Vice President, Manufacturing

Dr. Hershberg has more than 40 years of experience in biotechnology in the areas of recovery process development and large-scale manufacturing operations. He worked at Hoffmann LaRoche, Genentech, Immunex, and Amgen and has consulted for developing and major pharmaceutical companies. Dr. Hershberg had a major role in the development of ten commercial products encompassing cytokines, hormones, vaccines, blood factors, and antibodies. In addition, he worked in Pharmaceutical Sciences and contributed to the development of formulations for several commercial products. Dr. Hershberg received his Ph.D. from University of Pennsylvania in Biochemistry and a B.S. in chemistry from University of Pittsburgh. 

Curtis L. Scribner

Curtis L. Scribner, M.D.

Acting Vice President, Regulatory

Dr. Scribner is a board certified internal medicine specialist with long experience in drug development as a clinical investigator, regulatory reviewer, and strategic product life cycle consultant. He has extensive experience in virology and viral diseases, oncology, hepatology, infectious disease, rheumatology, immunology, very rare and Orphan diseases and gene therapy. Dr. Scribner was at the Center for Biologics Evaluation and Research (CBER), FDA, for 10 years, reviewing all phases of clinical development in a wide breadth of areas (including blood, plasma, recombinant proteins, cells, tissues, vaccines). Dr. Scribner was also Chief Regulatory Officer at a venture-based drug, biologic and combination development company (BioMedicines/Intarcia). He has more than 25 years of experience as a consultant to drugs and biologics companies working on everything from discovery and preclinical models through clinical trials, especially early stage clinical trials, Data Safety Monitoring Committees, and strategic and operational regulatory interactions in the US (FDA) and Europe (EMA and Member States). Dr. Scribner received his M.D. from the University of Colorado College of Medicine, an MBA from the University of Maryland School of Business, and a B.A. from Grinnell College. 

Board of Directors & Key Advisors

Malcolm Gefter

Malcolm L. Gefter, Ph.D.

Director

Dr. Gefter is Professor Emeritus of Biochemistry at the Massachusetts Institute of Technology. He founded Praecis Pharmaceuticals Inc. and was Chairman of the Board, CEO, President and/or Chief Scientific Officer until it was sold to GlaxoSmithKline. He founded ImmuLogic Pharmaceutical Corporation and served as its CEO and/or Chairman of the Board for 10 years. He has authored more than 200 peer reviewed scientific publications. Dr. Gefter received his B.S. in Chemistry from the University of Maryland and his Ph.D. in Molecular Biology from Albert Einstein College of Medicine.

Misha Petkevich

J. Misha Petkevich, D.Phil.

Director

Dr. Petkevich has more than 30 years of financial and investment experience in biotechnology and investment banking. He is currently the Chief Investment Officer of V2M Capital®, an investment firm funding life science companies. He previously co-founded BladeRock Capital, LLC, the predecessor investment firm to V2M Capital®. Prior to BladeRock Capital, Dr. Petkevich founded The Petkevich Group, a biotechnology advisory firm, where he was Chairman and Chief Executive Officer. Dr. Petkevich previously served as Managing Director, as well as Head of Healthcare and Investment Banking, at Robertson Stephens & Co. Dr. Petkevich began his career at Hambrecht & Quist, an investment bank, where he served as a Principal, Head of Healthcare Banking and as an Institutional Investor ranked biotechnology analyst covering Genentech, Chiron and others. Dr. Petkevich received his bachelor’s degree from Harvard University and his D.Phil. from the University of Oxford as a Rhodes Scholar. He also is a member of the Board of Directors at Cohbar, Inc.

Nicole Vitullo

Nicole Vitullo

Director

Ms. Vitullo has more than 30 years of experience in the biotech industry. She is a Partner at Domain Associates and has extensive experience in both public and private investing in biotech companies and liquidation/distribution strategies for public companies. For more than a decade, Ms. Vitullo was responsible for Domain Public Equity Partners L.P., a fund focused on private investments in public companies. Previous to Domain, Ms. Vitullo was senior vice president at Rothschild Asset Management, Inc., where she had responsibility for the U.S. public market investments of International Biotechnology Trust plc and Biotechnology Investments Limited. Prior to that, Ms. Vitullo served as the director of corporate communications and investor relations at Cephalon, a publicly traded biotechnology company, and held a number of positions at Eastman Kodak, including corporate development. Her current board memberships include Exalys, Inc., Esperion Therapeutics, and Marinus Pharmaceuticals. She is a board observer at Antios Pharmaceuticals. Previously, Ms. Vitullo served as Chairman of the Board at Achillion Pharmaceuticals (sold to Alexion) and served on the boards of Celator Pharmaceuticals (sold to Jazz Pharmaceuticals), Durata Therapeutics (sold to Activas PLC), Cerexa Therapeutics (sold to Forest Labs) and Calixa Therapeutics (sold to Cubist). Ms. Vitullo received her B.A. in mathematics and her MBA in finance from University of Rochester.

Bill Unger

Bill Unger

Director

Mr. Unger spent more than 20 years as a General Partner at venture capital firm Mayfield Fund where he was an early investor in industry leaders such as Sandisk, Silicon Architects, Calico Commerce, nChip, Newport Communications, Simplex Solutions, and Excess Bandwidth Corporation. More recently, he advised privately held companies, including Nextest, Berkeley Design Automation, D2S, Verplex and The @ Company. He also devotes significant time to philanthropic activities and currently serves as a board chair of Equalize Health, and as a director of CARE Enterprises, The Wildlife Conservation Network, and he is on the advisory board of the Dean of Engineering for the University of Illinois at Chicago. He received his B.A. from the University of Illinois at Chicago and is the recipient of an honorary Doctorate in Engineering from the University of Illinois at Chicago.

Carin Rollins

Carin Mueller Rollins, MBA

Director & Chief Executive Officer

Ms. Rollins has more than 25 years of experience in the biotechnology industry, particularly in the areas of venture capital, management consulting and equity research. She was a co-founder of early-stage life science venture capital firm, 5AM Ventures, where she incubated and was a founding member of the Board of Directors of Marcadia (purchased by Roche) and KaloBios (IPO). She was previously an Investment Manager at Bay City Capital, an Associate in the pharmaceuticals practice of Booz Allen & Hamilton, and an Equity Research Associate at the investment bank Robertson Stephens & Co. Ms. Rollins holds a B.A. in Biology from Colgate University, where she served as a Trustee, and an MBA from the Stanford Graduate School of Business.

Daniel Capon

Daniel Capon, Ph.D.

Director & Chief Scientific Officer

Dr. Capon is a molecular biologist with extensive experience in biotech invention and innovation. He holds forty-seven United States Patents covering recombinant Factor VIII for the treatment of hemophilia as well as several widely adopted foundational technologies including Fc fusion proteins, chimeric antigen receptors for T cell therapy, and genetically engineered mice using embryonic stem cells for the creation of fully human antibodies. His inventions have been broadly licensed and have led to the discovery and development of over twenty FDA-approved, marketed therapeutics including Enbrel for rheumatoid arthritis, Kymriah for B cell cancer, Vectibix for breast cancer, and Prolia/Xgeva for osteoporosis. Dr. Capon joined Genentech in 1981, serving in various positions including Staff Scientist and founding member of its Product Development Committee. He joined Cell Genesys in 1990, serving as Senior VP Research and Chief Technical Officer, and as a founder, director, and officer of Xenotech/Abgenix, a joint venture between Cell Genesys and Japan Tobacco, later acquired by Amgen for $2.2 billion. In 1995, Dr. Capon founded ViroLogic/Monogram Biosciences, today an operating subsidiary of LabCorp, serving as its Chairman and Chief Executive Officer to commercialize his invention of an HIV drug resistance diagnostic test used to guide HIV antiviral therapy. Dr. Capon has authored more than sixty peer-reviewed scientific publications. He received a B.S. in Biology and Ph.D. in Biochemistry from the Massachusetts Institute of Technology. 

Laura Brege

Laura Brege

Senior Advisor

Ms. Brege has more than 30 years of executive management experience in the pharmaceutical, biotechnology and venture capital industries. Most recently, she served as Managing Director of Cervantes Life Science Partners, LLC., a health care advisory and consulting company. She was previously Chief Executive Officer and President of Nodality, Inc. Prior to Nodality, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., including Executive Vice President and Chief Operating Officer, leading multiple functions, including commercialization, strategic planning, corporate development, and medical, scientific and government affairs. Prior to Onyx, Ms. Brege was a General Partner at Red Rock Capital Management, a venture capital firm specializing in early-stage financing for technology companies. Prior to Red Rock, Ms. Brege was Senior Vice President and Chief Financial Officer at COR Therapeutics, Inc. where she helped build the company from an early-stage research and development company through commercial launch of a successful cardiovascular product. Earlier in her career, she served as Chief Financial Officer at Flextronics, Inc. and Treasurer of The Cooper Companies. Ms. Brege currently serves on the boards of directors of Acadia Pharmaceuticals Inc., Pacira BioSciences, Inc., Edgewise Therapeutics, Inc., Mirum Pharmaceuticals, Inc. and HLS Therapeutics Inc., each of which is a public pharmaceutical company. Ms. Brege earned her undergraduate degree from Ohio University (Honors Tutorial College) and her MBA degree from the University of Chicago.

Samuel Broder

Samuel Broder, M.D.

Chair, Scientific Advisory Board

Dr. Broder has extensive experience as a scientist, oncologist, immunologist, and medical researcher. He is the former Director of the National Cancer Institute where he oversaw the development of numerous anti-cancer therapeutic agents and helped launch a number of large-scale clinical trials related to the prevention, diagnosis, and treatment of cancer and inaugurated the highly successful SPORE Program. His laboratory interests have included antiretroviral therapy, the relationship between immunodeficiency disorders and cancer, the human genome, and the proteomics of cancer cells. In particular, his laboratory was responsible for developing the first 3 agents approved by FDA specifically to treat the AIDS virus (Retrovir® (AZT), Videx® (ddI), and HIVID® (ddC)). After his tenure at the NCI, Dr. Broder served as Senior Vice President, Research and Development and Chief Scientific Officer at IVAX Corporation (now Teva Pharmaceuticals), as Executive Vice President for Medical Affairs and Chief Medical Officer at Celera Corporation and as Senior Vice President, Health Sector, Intrexon Corp. He currently serves as a member of the Board of Directors of Sensei Biotherapeutics and Geneos Therapeutics and sits on numerous scientific advisory boards. Dr. Broder is the author or co-author of over 340 scientific publications, and is an inventor on many patents. He has received numerous awards related to his research in cancer and AIDS and was elected to the National Academy of Medicine. He graduated from the University of Michigan Medical School, and did an internship and residency in Internal Medicine at Stanford and subspecialty training in medical oncology at the National Cancer Institute.